Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901

Journal of Clinical Oncology

Volumn 32, Issue 22, 2014, Pages 2318-2327

  Sheppard, Vanessa B ^a   Faul, Leigh Anne ^a   Luta, George ^a   Clapp, Jonathan D ^a   Yung, Rachel L ^b   Wang, Judy Huei Yu ^a   Kimmick, Gretchen ^c   Isaacs, Claudine ^a   Tallarico, Michelle ^a   Barry, William T ^c,d   Pitcher, Brandelyn N ^c,d   Hudis, Clifford ^f   Winer, Eric P ^b   Cohen, Harvey J ^c   Muss, Hyman B ^e   Hurria, Arti ^g   Mandelblatt, Jeanne S ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Cancer and Leukemia Group B Statistical Center   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g City of Hope   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRAILTY; GERIATRIC DISORDER; HEALTH CARE; HUMAN; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SELF REPORT; TUMOR INVASION; VERY ELDERLY; WEAKNESS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84905845243     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.7367     Document Type: Article

References (56)

1. Surveillance Epidemiology and End Results: SEER Stat fact sheets: Breast cancer. http://seer.cancer.gov/statfacts/html/breast.html
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
3. Demissie S, Silliman RA, Lash TL: Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322-328, 2001 (Pubitemid 32112842)
4. Neugut AI, Hillyer GC, Kushi LH, et al: Noninitiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 134:419-428, 2012
5. Silliman RA, Guadagnoli E, Rakowski W, et al: Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol 20:2680-2688, 2002 (Pubitemid 34575641)
6. Davies C, Godwin J, Gray R, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patientlevel meta-analysis of randomised trials. Lancet 378:771-784, 2011
7. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Senior adult oncology. http://www.nccn.org/professionals/physician- gls/f-guidelines.asp
8. Owusu C, Buist DS, Field TS, et al: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549-555, 2008 (Pubitemid 351264347)
9. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537, 2011
10. Barron TI, Connolly R, Bennett K, et al: Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 109:832-839, 2007 (Pubitemid 46333524)
11. Cluze C, Rey D, Huiart L, et al: Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: Determinants of interruptions vary over time. Ann Oncol 23:882-890, 2012
12. Fink A, Gurwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315, 2004 (Pubitemid 41103687)
13. Riley GF, Warren JL, Harlan LC, et al: Endocrine therapy use among elderly hormone receptorpositive breast cancer patients enrolled in Medicare part D. Medicare Medicaid Res Rev 1:e1-e25, 2011
14. van de Water W, Bastiaannet E, Hille ET, et al: Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: A TEAM study analysis. Oncologist 17:55-63, 2012
15. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001 (Pubitemid 32171549)
16. Rockwood K, Mitnitski A, Song X, et al: Longterm risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc 54:975-979, 2006 (Pubitemid 43847037)
17. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003 (Pubitemid 46621892)
18. Mandelblatt JS, Sheppard VB, Hurria A, et al: Breast cancer adjuvant chemotherapy decisions in older women: The role of patient preference and interactions with physicians. J Clin Oncol 1:3146-3156, 2010
19. Mandelblatt JS, Faul LA, Luta G, et al: Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B Protocol 369901. J Clin Oncol 30:2609-2614, 2012
20. Davis PB, Morris JC, Grant E: Brief screening tests versus clinical staging in senile dementia of the Alzheimer type. J Am Geriatr Soc 38:129-135, 1990 (Pubitemid 20048817)
21. Kawas C, Karagiozis H, Resau L, et al: Reliability of the Blessed Telephone Information-Memory- Concentration test. J Geriatr Psychiatry Neurol 8:238-242, 1995
22. Lash TL, Fox MP, Westrup JL, et al: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220, 2006 (Pubitemid 44268270)
23. Searle SD, Mitnitski A, Gahbauer EA, et al: A standard procedure for creating a frailty index. BMC Geriatr 8:24-2318-8-24, 2008
24. Schoufour JD, Mitnitski A, Rockwood K, et al: Development of a frailty index for older people with intellectual disabilities: Results from the HA-ID study. Res Dev Disabil 34:1541-1555, 2013
25. Gritz ER, Bastani R: Cancer prevention: Behavior changes - The short and the long of it. Prev Med 22:676-688, 1993 (Pubitemid 23311550)
26. Sheppard VB, Adams IF, Lamdan R, et al: The role of patient-provider communication for black women making decisions about breast cancer treatment. Psychooncology 20:1309-1316, 2011
27. Mandelblatt JS, Bierman AS, Gold K, et al: Constructs of burden of illness in older patients with breast cancer: A comparison of measurement methods. Health Serv Res 36:1085-1107, 2001 (Pubitemid 34016600)
28. Powe BD: Cancer fatalism among elderly Caucasians and African Americans. Oncol Nurs Forum 22:1355-1359, 1995
29. Scheier MF, Carver CS, Bridges MW: Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A reevaluation of the life orientation test. J Pers Soc Psychol 67:1063-1078, 1994
30. Sherbourne CD, Stewart AL: The MOS social support survey. Soc Sci Med 32:705-714, 1991
31. Makoul G, Arntson P, Schofield T: Health promotion in primary care: Physician-patient communication and decision making about prescription medications. Soc Sci Med 41:1241-1254, 1995
32. Safran DG, Taira DA, Rogers WH, et al: Linking primary care performance to outcomes of care. J Fam Pract 47:213-220, 1998 (Pubitemid 28433696)
33. Lin DY, Wei LJ, Ying Z: Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80:557-572, 1993
34. Kimmick G, Anderson R, Camacho F, et al: Adjuvant hormonal therapy use among insured, lowincome women with breast cancer. J Clin Oncol 27:3445-3451, 2009
35. McCowan C, Shearer J, Donnan PT, et al: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-1768, 2008
36. Fried LP, Ferrucci L, Darer J, et al: Untangling the concepts of disability, frailty, and comorbidity: Implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59:255-263, 2004 (Pubitemid 38375339)
37. Koller K, Rockwood K: Frailty in older adults: Implications for end-of-life care. Cleve Clin J Med 80:168-174, 2013
38. Gaillard S, Stearns V: Aromatase inhibitorassociated bone and musculoskeletal effects: New evidence defining etiology and strategies for management. Breast Cancer Res 13:205, 2011
39. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002 (Pubitemid 34694019)
40. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92:550-556, 2000 (Pubitemid 30212316)
41. Van Leeuwen BL, Rosenkranz KM, Feng LL, et al: The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol 79:315-320, 2011
42. Soubeyran P, Fonck M, Blanc-Bisson C, et al: Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 30:1829-1834, 2012
43. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
44. Pal SK, Katheria V, Hurria A: Evaluating the older patient with cancer: Understanding frailty and the geriatric assessment. CA Cancer J Clin 60:120-132, 2010
45. Kendal WS: Dying with cancer: The influence of age, comorbidity, and cancer site. Cancer 112:1354-1362, 2008
46. Schonberg MA, Davis RB, McCarthy EP, et al: External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc 59:1444-1451, 2011
47. Livaudais JC, Hershman DL, Habel L, et al: Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat 131:607-617, 2012
48. Bickell NA, Wang JJ, Oluwole S, et al: Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357-1362, 2006 (Pubitemid 46621998)
49. Banerjee M, George J, Yee C, et al: Disentangling the effects of race on breast cancer treatment. Cancer 110:2169-2177, 2007 (Pubitemid 350100737)
50. Liu Y, Malin JL, Diamant AL, et al: Adherence to adjuvant hormone therapy in low-income women with breast cancer: The role of provider-patient communication. Breast Cancer Res Treat 137:829-836, 2013
51. Murphy CC, Bartholomew LK, Carpentier MY, et al: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat 134:459-478, 2012
52. Font R, Espinas JA, Gil-Gil M, et al: Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: A retrospective cohort study in Catalonia, Spain. Br J Cancer 107:1249-1256, 2012
53. Farmer KC: Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074-1090, 1999; discussion 1073
54. Liu Y, Diamant AL, Thind A, et al: Validity of self-reports of breast cancer treatment in lowincome, medically underserved women with breast cancer. Breast Cancer Res Treat 119:745-751, 2010
55. Extermann M, Meyer J, McGinnis M, et al: A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49:69-75, 2004 (Pubitemid 38084822)
56. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007 (Pubitemid 46860271)